Roche immune therapy cancer drug shows promise in early study<p><a href="http://news.yahoo.com/roche-immune-therapy-cancer-drug-shows-promise-early-190305365--finance.html"><img src="http://l1.yimg.com/bt/api/res/1.2/yvbm4EVk_JEtsAgB_4Ieuw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-04-09T190305Z_1_CBRE9381GX900_RTROPTP_2_ROCHE-GENENTECH.JPG" width="130" height="86" alt="A logo is pictured on Swiss drugmakers Roche plant in Kaiseraugst" align="left" title="A logo is pictured on Swiss drugmakers Roche plant in Kaiseraugst" border="0" /></a>By Bill Berkrot (Reuters) - An experimental drug that spurs the immune system to fight cancer appeared to be safe and demonstrated anti-tumor activity against a variety of cancers in a small early stage study, researchers said on Tuesday. The drug, called MPDL320A, was discovered and is being developed by Roche's Genentech unit. The Phase 1 trial of the drug in 30 patients with advanced cancer was designed as a dose escalation study to test for toxicity at higher doses. But researchers were also pleased to find early signs of effectiveness of the drug. ...</p><br clear="all"/>
Source: Roche immune therapy cancer drug shows promise in early study (http://news.yahoo.com/roche-immune-therapy-cancer-drug-shows-promise-early-190305365--finance.html)